• Message from President
  • For Shareholders and Investors
  • Mid-term Management Plan
  • Profit Distribution Policies
  • Corporate Covernance
• IR Library
• IR Schedule
• IR News
• Financial Highlights
• Stock Information
• IR E-mail Alert

Message from President

Priority Goals for Corporate Value Improvement (3Ss)

The business environment facing the Seikagaku Group is continuously changing, as evidenced by expanded measures to control medical costs around the world, major corporate realignment, the intensification of the competition to develop new drugs, and increases in R&D costs. The social responsibilities that companies must demonstrate with regard to the economy, the environment, and society as a whole are also expanding.
The Seikagaku Group is focused on developing its business to be able to timely and adequately respond to this changing environment, and we are committed to maintaining a drive toward growth by focusing on the following three goals.

“Speed”
Strengthen the pharmaceutical business, the core business
for the Seikagaku Group

●Maintain and increase the sales of hyaluronic acid formulations

<Ensure growth potential in the domestic market>

We will increase our sales volume at a rate comparable to market growth in collaboration with our sales partners by supporting their sales activities, mainly through the provision of medical and scientific information and also by promoting product improvements that meet the needs of our customers. Furthermore, we will strive to increase the recognition of therapies that use hyaluronic acid products.

＜Increase our share in the US market and develop new markets＞

We are determined to increase sales in the US, currently the world's largest market for joint function improving agent, and to strengthen the competitiveness of our products. We are also committed to penetrating the potentially lucrative Chinese market and also to develop new markets with high growth potential over the medium to long term.

＜Establish a system for production increase＞

We will establish a stable production and supply system in order to respond to increased sales demands, through increasing production capability and adapting to the potential risk of disasters by constructing a new formulation facility.

●Enhance R&D activities with an eye to speed

We will increase our R&D capability by employing highly skilled R&D managers and by creating an R&D Division. We will also strive to bring our new products to the market as quickly as possible based on well-balanced implementation of in-house R&D activities, licensing activities, and collaboration with both Japanese and international companies and universities.

“Specialization”
Ensure the profitability of non-pharma businesses

We will strive to improve the profitability of our bulk products and our research biologics and diagnostics businesses, thus strengthening their business bases.

“Sustainability”
Fulfill corporate social responsibility

We will strive to improve our corporate governance by ensuring full compliance and further developing our internal systems to continuously retain the trust of our stakeholders, including shareholders. We will also strive to increase the transparency of our business and management through fair and timely disclosure of corporate information in a proactive manner.